Kalakhatta.com

Morphosys Incyte Agreement

December 13, 2020AdministratorUncategorized0

In January 2020, MorphoSys and Incyte signed a cooperation and licensing agreement for the development and commercialization of Tafasitamab worldwide. Monjuvi is co-marketed by Incyte and MorphoSys in the United States. Incyte holds exclusive marketing rights outside the United States. The MorphoSys Group, headquartered near Munich, employs 500 people, including the US subsidiary MorphoSys US Inc., which employs 100 people. For more information, see www.morphosys.com or www.morphosys-us.com. Contact Investor: Dr. Julia Neugebauer Director Tel: `49 (0)89 / 899 27 179 julia.neugebauer@morphosys.com Sophie Petersen Senior Specialist Tel: `49 (0)89 / 899 27 26033 sophie.petersen@morphosys.com The agreement between MorphoSys and Intecy, including participation, U.S. antitrust authorities are subject to approval by the Hart-Scott-Rodino Act and German and Austrian antitrust authorities and will come into force as soon as these conditions are met. In accordance with the agreement, the companies plan to launch a Phase 1/2 study to evaluate the association of tafasitamab, plamotamab and lenalidomide in patients with relapsed or refractory DLBCL. In addition, companies are considering evaluating the relapsed or front-line DLBCL combination in several Phase 1b studies. MorphoSys and Incyte will provide tafasitamab for Xencor-sponsored and funded studies in North America, Europe and the Asia-Pacific region. A live webcast is available in www.morphosys.com and on investor.incyte.com.

MorphoSys AG (FSE: MOR; standard premium segment; MDAX – TecDAX; NASDAQ: MOR) and Incyte Corporation (NASDAQ: INCY) announced today that the companies have entered into a cooperation and licensing agreement for the development and marketing of the anti-CD19 tafasitamab (MOR208) that owns Morphosys. Tafasitamab is a fc versus CD19 antibody currently in clinical development for the treatment of B cell malignon. MorphoSys and Incyte will co-market Tafasitamab in the United States, while Incyte holds exclusive marketing rights outside of the U.S. statements contained in this press release, which are not historical facts, are forward-looking statements within the meaning of applicable securities legislation, including, but not only, the quotes of Xencor`s Chairman and Executive; the result of collaboration with MorphoSys and Incyte, including the ability of cooperation to generate new clinical knowledge, accelerate developmental delays and accelerate patient care; The ability of the proposed combination of treatment to improve response rates and reach out to more patients in areas where need is not met; and the timing and success of the Phase 1/2 study and several Phase 1b studies under the agreement.

Comments are closed.